Dr Alexandros Kanellopoulos | Neuroscience | Best Researcher Award

Dr Alexandros Kanellopoulos Neuroscience | Best ResearcherAwardย  ๐Ÿ†

Principal Scientist of Cognitive Health atย DSM-Firmenich, RD Innovation
Switzerland๐ŸŽ“

Alexandros Kanellopoulos is a seasoned Innovation Leader, Principal Scientist, and Clinical Director with over 20 years of expertise in Neuroscience, Metabolism, Early Life Nutrition (ELN), and Medical Nutrition. He has successfully led multidisciplinary teams, pioneered product innovations, and authored more than 20 high-impact publications. With 7 patents to his name, Alexandros excels in transforming scientific research into tangible solutions that meet market needs.

Professional Profileย 

Education

Alexandros Kanellopoulos holds a Ph.D. in Neuroscience from Kapodistrian University, Greece (2008-2013), where his research focused on neurodevelopmental disorders. Prior to this, he completed his M.Sc. in Molecular Medicine (Neuroscience) at the same university (2005-2007), gaining advanced expertise in neuroscience and molecular biology. His academic foundation was established with a B.Sc. in Molecular Biology and Genetics from Dimocritus University of Thrace, Greece (2000-2005), where he developed a strong background in genetics and molecular biology.

Work Experience

In his current role as Global Principal Scientist & Clinical Director at DSM-Firmenich (2023-Present), Alexandros oversees scientific activities, driving innovation in dietary supplements and medical nutrition. Prior to this, he worked as an R&D Innovation Scientist and Project Manager at Nestle SA (2022-2023), leading the development of brain health products for Early Life Nutrition. In 2023, he also held the position of Medical, Scientific & Regulatory Affairs Manager at Nestle Nutrition, focusing on market communication and regulatory compliance. Alexandros previously served as Group Leader, Early Life Brain Metabolism at the University of Lausanne (2020-2022) and as Senior Scientist in Early Life Neuroscience (2016-2020), where he pioneered research in neurodevelopmental disorders.

Skillsย 

Alexandros is highly skilled in Innovation & Product Development, leading projects from concept to market. He is an expert in Clinical Research & Protocol Design, managing complex preclinical and clinical trials. His ability to lead multidisciplinary teams and drive Cross-functional Collaboration is complemented by his talent for Stakeholder Engagement & Market Alignment, ensuring alignment between research innovations and market needs. His Strategic Thinking, Problem-solving, and Emotional Intelligence are key to his success in high-impact research and business projects.

Awards & Honors

Throughout his career, Alexandros has earned more than 15 research awards, securing CHF 2.5 million in research funding. He has been awarded 7 patents as an inventor, reflecting his contributions to innovation in neuroscience and nutrition. In addition, he has delivered over 40 invited presentations at international conferences, establishing himself as a respected thought leader in his field.

ย Membershipย 

Alexandros contributes to the scientific community as a Reviewer for leading neuroscience journals and serves as an Editor in scientific publications, ensuring the dissemination of high-quality research.

Teaching Experience

Alexandros is also an experienced educator, having delivered lectures in Neuroscience and Medical Sciences at the University of Lausanne and Kapodistrian University, Athens. In his academic roles, he has mentored over 20 junior scientists, fostering the next generation of researchers and innovators.

Research Focus

Alexandros’ research centers on Early Life Nutrition and its role in brain development. He is particularly focused on Neurodevelopmental Disorders such as Autism and Fragile X Syndrome. His work on Brain Energy Metabolism and Mitochondrial Function provides insights into neurotransmission and social behavior. Alexandros has also designed Preclinical and Clinical Research aimed at developing nutritional solutions to address these complex medical challenges.

Publications :ย 

  • Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome
    ๐Ÿง  International Journal of Molecular Sciences โ€“ 2024
    DOI: 10.3390/ijms25168787
  • Aralar Sequesters GABA into Hyperactive Mitochondria, Causing Social Behavior Deficits
    ๐Ÿงฌ Cell โ€“ 2020
    DOI: 10.1016/j.cell.2020.02.044
  • Conserved Tao Kinase Activity Regulates Dendritic Arborization, Cytoskeletal Dynamics, and Sensory Function in Drosophila
    ๐Ÿ”ฌ The Journal of Neuroscience โ€“ 2020
    DOI: 10.1523/jneurosci.1846-19.2020
  • Domain-Specific Cognitive Impairments in Humans and Flies With Reduced CYFIP1 Dosage
    ๐Ÿงฉ Biological Psychiatry โ€“ 2019
    DOI: 10.1016/j.biopsych.2019.04.008
  • SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse
    ๐Ÿง  Neuron โ€“ 2019
    DOI: 10.1016/j.neuron.2019.05.002
  • Mitochondrial Dysfunction in Autism Spectrum Disorder: Clinical Features and Perspectives
    ๐Ÿง  Current Opinion in Neurobiology โ€“ 2017
    DOI: 10.1016/j.conb.2017.05.018
  • Autism Spectrum Disorders: Translating Human Deficits into Mouse Behavior
    ๐Ÿ Neurobiology of Learning and Memory โ€“ 2015
    DOI: 10.1016/j.nlm.2015.07.013
  • Learning and Behavioral Deficits Associated with the Absence of the Fragile X Mental Retardation Protein: What a Fly and Mouse Model Can Teach Us
    ๐Ÿง  Learning & Memory (Cold Spring Harbor, N.Y.) โ€“ 2014
    DOI: 10.1101/lm.035956.114
  • Learning and Memory Deficits Resulting from Reduction of the Fragile X Mental Retardation Protein: A Metabotropic Glutamate Receptor-Mediated Inhibition of cAMP Signaling in Drosophila
    ๐Ÿง  The Journal of Neuroscience โ€“ 2012
    DOI: 10.1523/JNEUROSCI.1347-12.2012
  • Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-blind, Placebo-controlled Study
    ๐Ÿ’Š The American Journal of Gastroenterology โ€“ 2011
    DOI: 10.1038/ajg.2011.179

Dr Andreu Massot Tarrรบs | Neuroscience | Best Researcher Award

Dr Andreu Massot Tarrรบs | Neuroscience | Best Researcher Award ๐Ÿ†

Neurologist at Hospital Universitari Mรบtua Terrassa, Spain๐ŸŽ“

Andreu Massot Tarrรบs, MD, PhD, is a highly accomplished neurologist and epileptologist with over 20 years of experience. He earned his Medical Doctorate from the Universitat Autรฒnoma de Barcelona in 2003 and later completed a PhD Cum Laude in Medicine, focusing on intracranial atherostenosis. He has held senior neurology positions at prestigious hospitals in Spain, including Hospital Universitari Vall dโ€™Hebron, Jimรฉnez Dรญaz Foundation, and Hospital Universitari Mรบtua Terrassa, where he currently serves. Dr. Massot Tarrรบs has specialized expertise in epilepsy, EEG, and cerebrovascular diseases and has completed advanced fellowships in Canada and the UK.

Professional Profileย 

Education

Andreu Massot Tarrรบs earned his Medical Doctorate in August 2003 from the Universitat Autรฒnoma de Barcelona. He went on to complete his Neurology specialization in May 2009 at the Hospital Universitari Vall dโ€™Hebron, Barcelona. In June 2013, he was awarded a PhD Cum Laude in Medicine by the same university for his thesis on intracranial atherostenosis, supervised by Dr. Montaner Villalonga and Dr. รlvarez-Sabรญn. His commitment to epilepsy research led him to a Clinical and Research Fellowship in Epilepsy and EEG at Western University, Ontario, in 2014, followed by a Master in Epilepsy from the Universidad de Murcia in 2018, where he received an excellent qualification.

ย Work Experience

Dr. Massot Tarrรบs’s medical career has spanned several prestigious institutions. Starting as a clinical observer in London (2008), he then became a Senior Neurologist in Barcelona and Madrid, working in the Neurovascular Unit at Vall dโ€™Hebron (2009-2010) and the Epilepsy Unit at the Jimรฉnez Dรญaz Foundation (2010-2011). Between 2011 and 2021, he took on various senior roles, including at Hospital del Mar and Hospital Universitario Gregorio Maraรฑรณn, Madrid. Since September 2021, he has been a Senior Neurologist and Epileptologist at Hospital Universitari Mรบtua Terrassa, where he continues to excel in treating neurological disorders, particularly epilepsy.

ย Skillsย 

Dr. Massot Tarrรบs is highly skilled in Electroencephalography (EEG) and Video-EEG monitoring. He has extensive experience in intraoperative electrocorticography, cortical stimulation mapping, and the Wada test. His expertise in cerebrovascular diseases and ultrasonography diagnostics has made him a leading lecturer at several top hospitals, including Vall dโ€™Hebron, Hospital del Mar, and Hospital Gregorio Maraรฑรณn.

Awards & Honors

He holds certifications in Electroencephalography from both the Canadian Society of Clinical Neurophysiology (2015) and the Spanish Society of Neurology (2016). He was also awarded a Cum Laude distinction for his doctoral work and has participated in advanced training like the NIH Stroke Scale Training by the National Stroke Association.

ย Membershipย 

Dr. Massot Tarrรบs is an active member of the Spanish Society of Neurology and has contributed significantly to clinical neurophysiology through his memberships in various international medical bodies.

ย Teaching Experience

Dr. Massot Tarrรบs has shared his knowledge extensively, offering lectures on epilepsy, neurovascular diseases, and ultrasonography techniques. He has taught at institutions like Jimรฉnez Dรญaz Foundation, Hospital del Mar, and Western University, where his work in EEG and cerebrovascular illness has helped shape the careers of future neurologists.

ย Research Focus

His research primarily focuses on epilepsy and ischemic cerebrovascular diseases. His PhD thesis, which examined markers of recurrence in intracranial atherostenosis, highlights his dedication to improving diagnostics and treatment outcomes in neurology. He continues to contribute to research on epilepsy and cerebrovascular conditions, aiming to reduce the recurrence of ischemic events in patients.

 

๐Ÿ“–Publications :ย 

  • ๐Ÿ“„ “Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program”
    Author: Massot-Tarrรบs, A.
    Journal: Epilepsia Open
    Year: 2023
    Volume: 8(3), pp. 918โ€“929
  • ๐Ÿ“Š “Risk factors for comorbid epilepsy in patients with psychogenic non-epileptic seizures. Dataset of a large cohort study”
    Author: Massot-Tarrรบs, A.
    Journal: Data in Brief
    Year: 2022
    Volume: 45, 108568
  • ๐Ÿง  “Roles of fMRI and Wada tests in the presurgical evaluation of language functions in temporal lobe epilepsy”
    Author: Massot-Tarrรบs, A.
    Journal: Frontiers in Neurology
    Year: 2022
    Volume: 13, 884730
  • ๐Ÿ’Š “Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice”
    Co-author: Massot-Tarrรบs, A.
    Journal: Epilepsy and Behavior
    Year: 2022
    Volume: 134, 108836
  • ๐Ÿ“ˆ “Factors associated with comorbid epilepsy in patients with psychogenic nonepileptic seizures: A large cohort study”
    Author: Massot-Tarrรบs, A.
    Journal: Epilepsy and Behavior
    Year: 2022
    Volume: 134, 108780
  • ๐Ÿงฉ “Cortical myoclonus associated with coeliac disease showing a characteristic EEG pattern: A case report”
    Author: Massot-Tarrรบs, A.
    Journal: Seizure
    Year: 2022
    Volume: 95, pp. 81โ€“83
  • ๐Ÿš‘ “Response to anakinra in new-onset refractory status epilepticus: A clinical case”
    Author: Massot-Tarrรบs, A.
    Journal: Seizure
    Year: 2022
    Volume: 94, pp. 92โ€“94
  • ๐Ÿฆ  “Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic”
    Co-author: Massot-Tarrรบs, A.
    Journal: European Journal of Neurology
    Year: 2021
    Volume: 28(10), pp. 3339โ€“3347
  • ๐Ÿ“‰ “Predicting outcome of patients with psychogenic nonepileptic seizures after diagnosis in an epilepsy monitoring unit”
    Author: Massot-Tarrรบs, A.
    Journal: Epilepsy and Behavior
    Year: 2021
    Volume: 120, 108004
  • ๐Ÿงฌ “E200K familial Creutzfeldt-Jakob disease. MRI, EEG, PET and neuropathological correlation in a family”
    Co-author: Massot-Tarrรบs, A.
    Journal: Neurologia
    Year: 2021
    Volume: 36(5), pp. 399โ€“401

 

Hussein Al-Hakeim | Neuroscience | Best Researcher Award

Prof Hussein Al-Hakeim | Neuroscience | Best Researcher Award ๐Ÿ†

Peofessor of Medical Biochemistry at University of Kufa, Iraq๐ŸŽ“

ย Professor Dr. Hussein Kadhem Al-Hakeim is a distinguished Iraqi academic specializing in Medical Biochemistry, Biological Psychiatry, Insulin Resistance, and Nanobiochemistry. Residing at 28 Al-Adala, Najaf, Iraq, he is currently affiliated with Kufa University. Dr. Al-Hakeim is well-recognized for his significant contributions to biochemistry and clinical chemistry in Iraq.

Professional Profileย 

Education๐ŸŽ“

Dr. Al-Hakeim earned his B.Sc. in Chemistry from the University of Mosul in 1991, followed by an M.Sc. in Medical Chemistry and a High Graduate Diploma in Clinical Biochemistry from Al-Nahrain University in 2000 and 2001, respectively. He completed his Ph.D. in Medical Chemistry at the same institution in 2004. Additionally, he holds a Diploma in International Law and Diplomatic Relations from Cairo Regional Center for Training and Arbitration, obtained in 2017.

ย ๐Ÿ’ผWork Experience

Dr. Al-Hakeim has held various leadership roles, including Head of the Department of Chemistry at Kufa University and the University of Karbala. He has served as the Assistant Dean and Chief of the Examination Committee at the College of Science, University of Karbala. His teaching career includes extensive experience as a lecturer in postgraduate studies across multiple universities in Iraq.

ย ๐Ÿ› ๏ธSkills

Dr. Al-Hakeim is an expert in Medical and Clinical Biochemistry, Nanobiochemistry, Insulin Resistance, and Stem Cell Technology. He has a profound knowledge of biostatistics, biosensors, and protein-nanoparticle interactions, and is skilled in advanced laboratory techniques and various biochemical analysis methods.

ย ๐Ÿ†Awards and Honors

Dr. Al-Hakeim’s work has been recognized at numerous scientific congresses and conferences worldwide. His research contributions and academic leadership have earned him a prominent place in Iraq’s scientific community.

ย Membership ๐Ÿ›๏ธand Affiliations ๐Ÿค

Dr. Al-Hakeim is an active member of several scientific committees and associations. He frequently participates in international conferences and has presented his research at numerous prestigious events.

ย Teaching Experience๐Ÿ‘จโ€๐Ÿซ

Dr. Al-Hakeim has taught a wide range of courses at the B.Sc., M.Sc., and Ph.D. levels. His subjects include Advanced Biochemistry, Clinical Biochemistry, Toxicology, Endocrinology, Biostatistics, and more. He has also coordinated several courses and training programs, contributing significantly to the academic development of his students.

ย Research Focus ๐Ÿ”ฌ

Dr. Al-Hakeim’s research interests encompass Medical Biochemistry, Clinical Chemistry, Insulin Resistance Mechanisms, Stem Cell Technology, Nanobiochemistry, and the Medical Applications of Surface Chemistry. His work is particularly focused on protein-nanoparticle interactions, a field where he has made substantial contributions.

๐Ÿ“–Publications :ย 

  • IL-6, IL-18, sIL-2R, and TNFฮฑ proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation
    • ๐Ÿ—“๏ธ Year: 2015
    • ๐Ÿ“š Journal: Journal of Affective Disorders
  • Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses, and inflammation: a proof of concept
    • ๐Ÿ—“๏ธ Year: 2023
    • ๐Ÿ“š Journal: Molecular Psychiatry
  • Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients
    • ๐Ÿ—“๏ธ Year: 2011
    • ๐Ÿ“š Journal: Asian Journal of Transfusion Science
  • Intersections between pneumonia, lowered oxygen saturation percentage, and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID
    • ๐Ÿ—“๏ธ Year: 2021
    • ๐Ÿ“š Journal: Journal of Affective Disorders
  • The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments
    • ๐Ÿ—“๏ธ Year: 2022
    • ๐Ÿ“š Journal: Molecular Psychiatry
  • The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: a systematic review and meta-analysis
    • ๐Ÿ—“๏ธ Year: 2022
    • ๐Ÿ“š Journal: medRxiv
  • Serum levels of lipids, calcium, and magnesium in women with hypothyroidism and cardiovascular diseases
    • ๐Ÿ—“๏ธ Year: 2009
    • ๐Ÿ“š Journal: Journal of Laboratory Physicians
  • High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, andโ€ฆ
    • ๐Ÿ—“๏ธ Year: 2020
    • ๐Ÿ“š Journal: Schizophrenia Bulletin
  • IL-10 is associated with increased mu-opioid receptor levels in major depressive disorder
    • ๐Ÿ—“๏ธ Year: 2019
    • ๐Ÿ“š Journal: European Psychiatry
  • Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precisionโ€ฆ
    • ๐Ÿ—“๏ธ Year: 2023
    • ๐Ÿ“š Journal: Acta Neuropsychiatrica
  • The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated withโ€ฆ
    • ๐Ÿ—“๏ธ Year: 2023
    • ๐Ÿ“š Journal: Journal of Affective Disorders
  • Serum interleukin levels and insulin resistance in major depressive disorder
    • ๐Ÿ—“๏ธ Year: 2018
    • ๐Ÿ“š Journal: CNS & Neurological Disorders – Drug Targets
  • Lowered quality of life in long COVID is predicted by affective symptoms, chronic fatigue syndrome, inflammation, and neuroimmunotoxic pathways
    • ๐Ÿ—“๏ธ Year: 2022
    • ๐Ÿ“š Journal: International Journal of Environmental Research and Public Health
  • Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severityโ€ฆ
    • ๐Ÿ—“๏ธ Year: 2020
    • ๐Ÿ“š Journal: CNS Spectrums
  • The tryptophan catabolite or kynurenine pathway in major depressive and bipolar disorder: A systematic review and meta-analysis
    • ๐Ÿ—“๏ธ Year: 2022
    • ๐Ÿ“š Journal: Brain, Behavior, & Immunity – Health
  • The neuroimmune and neurotoxic fingerprint of major neurocognitive psychosis or deficit schizophrenia: a supervised machine learning study
    • ๐Ÿ—“๏ธ Year: 2020
    • ๐Ÿ“š Journal: Neurotoxicity Research
  • Serum apelin and galectin-3 in preeclampsia in Iraq
    • ๐Ÿ—“๏ธ Year: 2020
    • ๐Ÿ“š Journal: Hypertension in Pregnancy
  • Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia
    • ๐Ÿ—“๏ธ Year: 2020
    • ๐Ÿ“š Journal: Current Topics in Medicinal Chemistry
  • Estimation of Serum Copper, Manganese, Selenium, and Zinc in Hypothyroidism Patients
    • ๐Ÿ—“๏ธ Year: 2009
    • ๐Ÿ“š Journal: IUFS Journal of Biology
  • Major depression in children with transfusion-dependent thalassemia is strongly associated with the combined effects of blood transfusion rate, iron overload, and increased proโ€ฆ
    • ๐Ÿ—“๏ธ Year: 2020
    • ๐Ÿ“š Journal: Neurotoxicity Research

K S V POORNA CHANDRIKA | Cognitive Development| Best Researcher Award

Dr. K S V POORNA CHANDRIKA | Cognitive Development| Best Researcher Award

Dr.K S V POORNA CHANDRIKA,ICAR-Indian Institute of Oilseeds Research, Tiruchirappalli,India

Dr. K S V Poorna Chandrika is a prominent scientist affiliated with the ICAR-Indian Institute of Oilseeds Research in Tiruchirappalli, India. Her research primarily focuses on various aspects of oilseed crops, including breeding, genetics, and sustainable agricultural practices. Dr. Poorna Chandrika has made significant contributions to the field through her extensive research and publications, aiming to enhance crop productivity and resilience in challenging agricultural environments. Her work is highly regarded within the scientific community for its practical implications in improving food security and agricultural sustainability.

Professional Profile:

Area of Expertise:

  • Synthesis and characterization of hydrophilic superabsorbent and superporous hydrogels
  • Development of polymeric films as carriers for crop protection inputs
  • Formulation of microbial bioagents and chemicals for seed health and nutrient management
  • Instrumentation expertise: GLC, HPLC, UV spectroscopy, NMR, Electron microscopy, FT-IR, HPTLC, GC, XRD, AAS, DLS, rheometer, ICP, DSC etc.

Contribution to Scientific Advancement:

  • Developed potential polymeric films for management of biotic and abiotic stresses in various pulses and oilseeds
  • Field evaluation of innovative formulations for sustainable agriculture

Awards and Recognition:

    • Best Paper Award at IIOR-2019 for “Development of chitosan-PEG blended films using Trichoderma: Enhancement of antimicrobial activity and seed quality”
    • Best Oral Presentation Award at International Bio Pesticide Conference-2019

Area of Research:

    • Currently researching polymers as formulation carriers and nanosystems for various delivery mechanisms

Publications:ย 

  • Hydrogels and Superabsorbent Materials: Chandrika KSVP has contributed significantly to research on novel hydrogels, particularly those based on guar gum and poly(acrylate). These hydrogels are characterized for their superabsorbent properties and their behavior in different environments, including simulated environments and plant growth media.
  • Biopesticides and Agricultural Applications: Chandrika KSVP has also explored nanobiopesticides and biopolymeric formulations for agricultural applications. This includes the development of Bacillus thuringiensis-based nanopesticides and other bioformulations for pest management and crop protection.
  • Biopolymer Blends and Coatings: Research extends to the development of biopolymer blends, such as chitosan-PEG films and chitosan-based seed coatings. These innovations aim to enhance antimicrobial activity, seed quality, and stress tolerance in crops against biotic and abiotic factors.
  • Nanotechnology in Agriculture: Chandrika KSVP has contributed to studies involving metal nanoparticles as plant nutrients and their applications through soil application. This includes research on Fe and Zn metal nanocitrates.
  • Patents and Innovations: There are mentions of patents related to polymer compositions and their preparation, indicating a focus on translating research into practical applications and intellectual property.